Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | RCHY1 |
| Gene Name: | RCHY1 |
| Protein Full Name: | RING finger and CHY zinc finger domain-containing |
| Alias: | Androgen-receptor N-terminal-interacting protein; ARNIP; CHIMP; CH-rich interacting match with PLAG1; PIRH2; RNF199; Zinc finger protein 363; ZN363; ZNF363 |
| Mass (Da): | 30110 |
| Number AA: | 261 |
| UniProt ID: | Q96PM5 |
| Locus ID: | 25898 |
| COSMIC ID: | RCHY1 |
| Gene location on chromosome: | 4q21.1 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19806 |
| Percent of cancer specimens with mutations: | 0.15 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | RCHY1 is a RING finger and CHY zinc finger domain-containing protein that has ubiquitin ligase activity and can mediate E3-dependent ubiquitination and proteasomal degradation of various proteins including the tumour suppressor p53/TP53 and histone deacetylase-1. Degradation of the p53/TP53 would lead to cell cycle progression, cell growth, and tumour progression. It can also increase the transcription activity of the steroid receptor AR. RCHY1 has been noted to be overexpressed in as much as 84% of lung cancers. |